Covidh Board approves preferential issue via share swap; capital up to ₹25 Cr

The Board of Directors of iSERA Lifesciences Limited (formerly Covidh Technologies Ltd) met on April 21, 2026, and approved several key matters. The authorized share capital was increased from ₹11 Crore to ₹25 Crore. The Board also approved the adoption of new Memorandum and Articles of Association to align with the Companies Act, 2013. Additionally, limits for investments, loans, or guarantees under Section 186 of the Companies Act, 2013 were enhanced to ₹1,000 Crore. Crucially, the Board approved valuation reports and the swap ratio for a proposed preferential issue of equity shares on a share swap basis, with iSERA Lifesciences' shares valued at ₹48.15. All these approvals are subject to shareholder approval via postal ballot/e-voting.